HTR1B and fragile X syndrome: We will continue efforts to develophighly selective ligands for 5-HT1B as well as 5-HT1D receptors using the 5-SAT platform given the chemotype,as represented by (2S)-FPT, appearsto be safe as well as effective, for example, in animal models ofsubstance use disorder55 as well as autismand fragile X syndrome.44−46